P339: BOOSTING THE EFFICACY OF CD20‐TARGETING IMMUNOTHERAPY IN B CELL ACUTE LYMPHOBLASTIC LEUKEMIA.

Autor: Poprzeczko, M., Domka, K., Pastorczak, A., Fidyt, K., Komorowski, L., Winiarska, M., Dabkowska, A., Siudakowska, K., Wojciechowska, A., Patkowska, E., Firczuk, M.

Publikováno v: HemaSphere; 2022 Supplement 3, Vol. 6, p239-240, 2p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20 ⁺ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models.

Autor: Domka K; Laboratory of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland; Department of Immunology, Medical University of Warsaw, Warsaw., Dąbkowska A; Laboratory of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland; Department of Immunology, Medical University of Warsaw, Warsaw., Janowska M; Laboratory of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw., Urbańska Z; Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland; Department of Genetic Predisposition to Cancer, Medical University of Lodz, Lodz., Pastorczak A; Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland; Department of Genetic Predisposition to Cancer, Medical University of Lodz, Lodz., Winiarska M; Laboratory of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland; Department of Immunology, Medical University of Warsaw, Warsaw., Fidyt K; Department of Immunology, Medical University of Warsaw, Warsaw., Lachota M; Laboratory of Cellular and Genetic Therapies, Medical University of Warsaw, Warsaw, Poland; Department of Ophthalmology, Children's Memorial Health Institute, Warsaw., Patkowska E; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw., Sędek Ł; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice., Perkowski B; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice., Hunia J; Department of Immunology, Medical University of Warsaw, Warsaw., Jakubowska J; Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz., Krzymieniewska B; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw., Lech-Marańda E; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw., Młynarski W; Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz., Szczepański T; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice., Firczuk M; Laboratory of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, Poland; Department of Immunology, Medical University of Warsaw, Warsaw. mfirczuk@imdik.pan.pl.

Publikováno v: Haematologica [Haematologica] 2024 Nov 01; Vol. 109 (11), pp. 3520-3532. Date of Electronic Publication: 2024 Nov 01.